Find the best CNRS technologies to boost your innovative project.
06.11.2018
Materials – Coating 07293-01
06.11.2018
Materials – Coating 10581-01
06.11.2018
Chemistry / Environment 08758-01
06.11.2018
11127-01
06.11.2018
Environment and Energy 11107-01
19.10.2018
Medical Diagnostic 08504-01
We can guide you through the whole technology transfer process.
Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.
06433-01
Priority patent application n° FR 14 51740 filed on March 04, 2014, and entitled “Nouvelles lectines et applications pour la détection de marqueurs d’états pathologiques.”
Anne IMBERTY, Julie ARNAUD, Aymeric AUDFRAY
Exclusive or non-exclusive license
Centre de recherches sur les macromolécules végétales (CERMAV,UPR5301 ), Grenoble, France.
Changes in cell surface glycosylation are known to be associated with a large number of chronic diseases and the cancer glycans represent a very promising field for biomarker discovery. Among them, specific glycans, such as those terminated by N-acetylglucosamine (GlcNAc) residues are rare on healthy tissues. Other oligosaccharides, rich in fucose (Fuc) residues are markers of inflammation. Lectins have been demonstrated to be very efficient for detecting aberrant glycosylation in biological samples. A new technology is the use of lectin arrays that can contain lectins with large spectra of specificity and therefore characterize variation of glycosylation. The use of lectins extracted from natural organisms may be time-consuming and may generate problems of contamination or variations between batches. Therefore, recombinant lectin technology is starting to be developed.
The present invention relates to recombinant multimeric lectins having a beta-propeller architecture, formed from repetition and/or oligomerisation of 4 to 7 modules of approximately 30 to 60 amino acids. The concept of neolectins consist in modifying first the valency, creating a monovalent lectin for which the specificity can be engineered, then recreating lectins with chosen number of active binding sites.
These neolectins have important advantages over extracted lectins. They are recombinant proteins, with higher purity (no contamination) and higher reproducibility than lectins purified from plants of invertebrates. There specificity and valency can be modified to be adapted for recognition of specific epitopes. They are easier, cheaper and faster to produce than antibodies.
This innovation could be used for: – Glycobiology research – Quality control of recombinant glycoproteins (for example for characterizing the glycosylation of therapeutic antibodies) – Diagnostic / Prognostic / Therapeutic follow-up of cancers as leukaemia, adenocarcinoma, kidney, breast and ovary carcinoma, … but also others diseases as rheumatoid arthritis, elderly dementia, … – Diseases treatment, particularly cancers (for drug vectorisation)
Accomplished tests: – Production of recombinant lectin from Psathyrella velutina (GlcNAc specific) and Burkholderia ambifaria (Fuc specific) – Production of neolectins from Ralstonia solanacearum with controlled valency – Labeling of human cancer cells and carcinoma tissues Current developments: Modifying the specificity of lectin through phage display approach (Ref 06433-01)
For further information, please contact us (Ref 06433-01)
08.02.2017
Chemistry / Environment, Health / Therapeutic, Medical Diagnostic, Materials – Coating 00957-03
27.07.2015
Health / Therapeutic, Other Technologies 01418-01
05.06.2015
Medical Diagnostic 06100-01
06.11.2018
Materials – Coating 07293-01
06.11.2018
Materials – Coating 10581-01
06.11.2018
Chemistry / Environment 08758-01
06.11.2018
11127-01
06.11.2018
Environment and Energy 11107-01
19.10.2018
Medical Diagnostic 08504-01